David A. Siegel Cara Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CARA
# of Institutions
74Shares Held
12.8MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA2.25MShares$674,6730.0% of portfolio
-
Chescapmanager LLC Baltimore, MD1.7MShares$510,6330.06% of portfolio
-
Farallon Capital Management LLC San Francisco, CA1.56MShares$466,8750.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN1.11MShares$333,9120.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.11MShares$332,6790.0% of portfolio
About Cara Therapeutics, Inc.
- Ticker CARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,725,900
- Market Cap $16.1M
- Description
- Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...